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Injection Sclerotherapy of Bleeding Esophageal Varices:
The Henry Ford Hospital Experience
Stephen R. Verbeck, MD,* Martin C. Zonca, MD,' and Dominic K.H. Wong, MD^

An update is provided of our ongoing sclerotherapy experience at Henry Ford Hospital, based on 47
patients who have undergone this procedure. One-month mortality rates for Child's classes C. B. and
A were 50%. 22%. and 0%, respectively. Follow-up after one month revealed ten additional
mortalities, but none were secondary to esophageal variceal hemorrhage. Strictures secondary to
sclerotherapy were amenable to dilation. We advocate sclerotherapy as the treatment of choice for
esophageal variceal hemorrhage. (Henry Ford Hosp Med J 1986:34:120-2)

S

clerotherapy has become an accepted therapeutic modality
for treatment of bleeding esophageal varices. The procedure
has become more developed over the last five years and is now
widely available. The high mortality of surgical intervention in
acute variceal bleeding further necessitates the need for a low
risk, efficacious treatment to control esophageal variceal bleeding. We present an update on the technique, complications, and
efficacy of this procedure, based on our ongoing experience
with this modality of therapy.

Methods
Injection therapy is performed using the Olympus 2T panendoscope, Olympus XQ-10 endoscope, or the Fujinon endoscope. Balloon attachments initially employed are no longer
deemed necessary (1). Injections are made using a Sivak retractable needle. Our sclerosant of choice is 5% sodium morrhuate,
but we have also used 0.75% sodium tetradecyl. All injections
are intended to be intravariceal using 2 mL of the sclerosing
agent with a maximum of 15 injections per session. Inpatients
are treated every other day during the acute phase, with a maximum of four sessions in two weeks. Injections were made at
intervals not longer than eight weeks, with patient compliance
and if patient condition permitted. Patients were then followed at
three month to yearly intervals.

Table 1
Etiology of Cirrhosis Versus Child's Classification
Child's Class

C

B

A

Alcohol
Cryptogenic
Buidd Chiari
Occluded shunt and alcohol
Hepatitis B and alcohol
Portal splenic vein thrombosis
Primary biliary cirrhosis
CAH-Schistosoma

14
4

12
2
1

6
2

—

—

1
1
1

—

—
—

—
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1
1

—
—
—
—
1
1

Patients
Patients are considered for sclerotherapy if any of the followingfindingsare present: 1) active variceal bleeding at thetimeof
endoscopy; 2) signs of recent variceal hemorrhage, ie, adherent
clots or cherry-red spots on the varix; and 3) recent upper gastrointestinal bleeding with varices present, but no other lesions
visualized at the time of endoscopy. Data were collected frora
June 1980 to 1984; a total of 47 patients are included in this
review. Data regarding etiology of liver disease and modified Child's classification are provided in Table I . Modified
Child's classification was determined by the criteria of Pugh et al
(Table 2) (2).

Table 2

Risk Classification of Sclerotherapy Patients*
1
Encephalopathy
Ascites

Nil
Nil

2
Mild to
moderate
Slight

3
Severe
Moderate
to severe

Bilimbin
(mg/lOO mL)
Albumin
(g/100 mL)
Prothrombin index
Risk grade numerical score
A ( = I)
5-6
B ( = 2)
7-9
C ( = 3)
10-15
*From Pugh et al (2).

3.5
70%

2-3

>3

2.8-3.5
40%-70%

< 2.8
< 40%
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Table 3
Course of Early Mortality Versus Child's Classification
gafly Mortality
^jgoholic cirrhosis, bleeding primary
cause of death
/alcoholic cirrhosis, bleeding at time
but not primary cause of death
yUcoholic cirrhosis, not bleeding
Nonalcoholic cirrhosis, bleeding
primary cause of death
Nonalcoholic cirrhosis, bleeding at
time but not primary cause of death
Nonalcoholic cirrhosis, not bleeding

le followle time of
adherent
pper gaser lesions
eted from
ed in this
nd modiModified
Pugh et al

3
Severe
Moderate
to severe
> 3
< 2.8
< 40%

iital.
b St. Akron. OH
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C

B

A

2

2

0

4
2

0
1

0
0

0

0

0

1
1

0
1

0
0

Results
Within 30 days after entry into the sclerotherapy protocol, 14
ofthe 47 patients died from various causes including bleeding,
respiratory failure, aspiration pneumonia, sepsis, and hepatorenal syndrome (Table 3). Thirty-three patients survived the
first 30 days and had follow-up with repeat sclerotherapy as
needed for rebleeding or at convenient elective intervals. A total
of 40 episodes of rebleeding were seen in the 33 long-term survival patients. In 32 patients, rebleeding either stopped spontaneously with conservative support (ie, pitressin, transfusion,
or Blakemore tube) or was controlled with repeat sclerotherapy.
One rebleeding patient elected to have a splenorenal shunt.
When repeat endoscopy was performed, many patients were
noted to have superficial ulcerations, but these had resolved by
the time of follow-up examinations. Many ulcerations required
no treatment, although sucralfate (Marion Laboratories, Kansas
City, MO) prepared in suspension was helpful in healing less
transient ulcerations. Nine patients subsequently developed benign stricture; six of the nine patients became symptomatic and
thus required dilation. Overall mortality statistics for the 47 patients reviewed are provided in Table 4.
In Child's class C (20 patients), mortality was 50% within one
month, with seven of these ten deaths directly related to bleeding. Five additional deaths in this group occurred after the first
30 days, with a survival range of two to 45 months (average 13
months). None of the later deaths were related to variceal hemorrhage. Follow-up of surviving patients ranged from three to 50
months (average 19 months). In Child's class B (17 patients),
mortality was 24%, with only two of four deaths related to
bleeding. Four additional deaths occurred in the follow-up period: one at three months, one at five months, and two at 18
months subsequent to enrollment. Three deaths were not related
to variceal hemorrhage, and one patient's cause of death was unknown. Follow-up of survivors ranged from two to 22 months,
with an average of nine months. In Child's class A, no mortality
was seen within the first 30 days. One patient died 11 months
after sclerotherapy, secondary to spread of hepatocellular carcinoma. Follow-up of survivors ranged from six to 36 months
with an average of 22 months.
All strictures encountered secondary to sclerotherapy were
dilated with good results, except for one patient who was
noncompliant to medication therapy and who continued to
<^tink alcohol. Temperature, pain in the chest, and pleural effusions were noted infrequentiy and were transient in nature. No
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Table 4
Mortality Versus Child's Classes A, B, and C
Child's Class
C
B
A

Within One Month
10/20
4/17
0/10

To Date
15/20
8/17*
1/10*

*Two patients lost to follow-up,

esophageal perforations were discovered. One patient elected
shunt surgery after rebleeding, and sclerotherapy was initiated in at least one patient after shunt therapy failed to control
bleeding.

Discussion
This series represents our ongoing experience with endoscopic sclerotherapy. When varices are present, approximately
30% will bleed, but after the initial hemorrhage approximately
70% will experience rebleeding (3). Graham and Smith (4) reported mortality of 42% within six weeks of index hemorrhage,
with only 33% surviving one year. Considering such high mortality rates, efforts were made to prevent variceal hemorrhage by
prophylactic portacaval shunting. Studies by Conn et al, however, showed no survival benefits with such surgery (5). At present, most therapy for variceal hemorrhage starts after the initial
hemorrhage.
Various surgical procedures have been proposed over the
years. Presently, the two most favored procedures are the portacaval shunt and the distal-splenorenal, which is also known as
the Warren shunt. The Warren shunt compared to the portacaval
shunt offers the advantage of lower incidence of encephalopathy
(23% versus 40%), but is technically more difficult to perform
(6). Surgical mortality in emergency situations varies widely
(0%-87%), with mortality most marked in patients of Child's
class C (6-9). Acute nonsurgical management of variceal hemorrhage includes balloon tamponade and vasopressin. The
Sengstaken-Blakemore tube is effective in controlling hemorrhage in 80%-90% of cases, but bleeding may recur when the
tube is deflated or removed (10). Sengstaken-Blakemore tube
placement also carries significant risks, including aspiration,
esophageal rupture or laceration, and airway occlusion. Oral
propranolol has been advocated for control of recurrent variceal
hemorrhage (I I), but recent publications have questioned this
benefit and recommend further clinical trials (12). In addition,
propranolol may block normal hemodynamic response to hemorrhage by beta-blockade. Intravenous vasopressin has been advocated as palliation until definitive therapy is performed (13).
Sclerotherapy was first described by Crafoord and Frenckner
in 1939 (14), and was reintroduced by Palmer in 1954 (15). The
technique was revived in the mid- 1970s, and reports in the worid
literature and experience with the technique have grown exponentially since then. Sivak et al (16) reported a decreased
transfusion requirement in long-term follow-up of patients undergoing esophageal injection sclerotherapy. Cello et al have recentiy conducted trials which show comparable survival rates in
Child's class C patients with variceal hemorrhage treated by either portacaval shunt or sclerotherapy (17). In addition, the cost
of sclerotherapy was significantiy less when compared to shunt
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therapy. Sclerotherapy did not appear to improve the immediate
mortality secondary to the acute variceal bleeding episode, but
its main effect (ie, reduced mortality) has been shown in the
long-term groups (18). The possibility of improved overall survival in variceal hemorrhage remains unresolved.
The 50% early mortality rate in Child's class C patients was
not unexpected. These patients have a high incidence of encephalopathy and hepatorenal syndrome and are predisposed to
bleeding complications secondary to coagulopathy. Sclerotherapy should be helpful in reducing the high transfusion demands of these patients.
At present, we consider sclerotherapy as the treatment of
choice for all variceal bleeding. In Child's classes A and B,
no clear guidelines for treatment planning exist, but in consideration of our positive results with these patients, we feel comparative trials of sclerotherapy versus portacaval shunts are
warranted. In our opinion, sclerotherapy is a safe, effective
means for controlling hemorrhage, reducing transfusion requirements, and possibly improving long-term survival.
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